The stock of Entero Therapeutics Inc (ENTO) has seen a -7.40% decrease in the past week, with a -10.69% drop in the past month, and a -2.02% decrease in the past quarter. The volatility ratio for the week is 9.93%, and the volatility levels for the past 30 days are at 13.60% for ENTO. The simple moving average for the last 20 days is -15.95% for ENTO stock, with a simple moving average of -19.01% for the last 200 days.
Is It Worth Investing in Entero Therapeutics Inc (NASDAQ: ENTO) Right Now?
Company’s 36-month beta value is 0.78.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for ENTO is 4.44M, and currently, short sellers hold a 6.45% ratio of that floaft. The average trading volume of ENTO on July 04, 2025 was 1.64M shares.
ENTO stock’s latest price update
Entero Therapeutics Inc (NASDAQ: ENTO) has seen a decline in its stock price by -0.54% in relation to its previous close of $0.41. However, the company has experienced a -7.40% decline in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-06-13 that Calgary, Alberta–(Newsfile Corp. – June 13, 2025) – FluroTech Ltd. (TSXV: TEST.H) (“FluroTech” or the “Company”) is pleased to announce that effective June 12, 2025, Eric Corbett has been appointed to the board of directors.
ENTO Trading at -6.17% from the 50-Day Moving Average
After a stumble in the market that brought ENTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.28% of loss for the given period.
Volatility was left at 13.60%, however, over the last 30 days, the volatility rate increased by 9.93%, as shares sank -10.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.83% upper at present.
During the last 5 trading sessions, ENTO fell by -7.40%, which changed the moving average for the period of 200-days by +15.42% in comparison to the 20-day moving average, which settled at $0.4792. In addition, Entero Therapeutics Inc saw -64.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTO starting from Romano Sarah, who sold 727 shares at the price of $0.64 back on Jan 06 ’25. After this action, Romano Sarah now owns 17,287 shares of Entero Therapeutics Inc, valued at $465 using the latest closing price.
Romano Sarah, the Chief Financial Officer of Entero Therapeutics Inc, sale 476 shares at $0.45 during a trade that took place back on Oct 09 ’24, which means that Romano Sarah is holding 18,014 shares at $212 based on the most recent closing price.
Stock Fundamentals for ENTO
The total capital return value is set at -0.27%. Equity return is now at value -33.24%, with -25.32% for asset returns.
Based on Entero Therapeutics Inc (ENTO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -65.59. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -237.88.
Currently, EBITDA for the company is 15606.71 with net debt to EBITDA at 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.
Conclusion
In a nutshell, Entero Therapeutics Inc (ENTO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
